V
Last Price
52 Week Range
DKK5.98 - DKK17.40
Next Earnings Date
-
Next Earnings Date
-
Last Price
Market Cap | DKK124.84M |
EV | DKK120.50M |
Shares Outstanding | 9.28M |
Beta | 0.90 |
Industry | Medical - Devices |
Analyst Rating | - |
Analyst Target Price | - |
Number of Analysts | 0 |
P/E 2025E | - |
P/Revenue 2025E | - |
Revenue | |
EPS | |
Operating Cash Flow | |
Free Cash Flow |
Revenue | |
EPS | |
Operating Cash Flow | |
Free Cash Flow |
Gross Margin 2025E | - |
Net Profit Margin 2025E | - |
ROE 2025E | - |
ROCE 2024 | -103.19% |
DPS 2025E | - |
Payout Ratio 2025E | - |
Div. Yield 2025E | - |
DPS Last 3Y CAGR |
Price
%
1M
3M
6M
1Y
3Y
5Y
V
ViroGates A/S
VIRO
Sector
Healthcare
Industry
Medical - Devices
CEO
Knudsen, Jakob
Employees
7
Website
www.virogates.comIPO Date
2018-06-26
Headquarters
Banevaenget 13, Birkerød, Capital Region of Denmark, 3460, Denmark
The last closing price of ViroGates (VIRO) is DKK13.45, reflecting a +11.16% change from the prior session. Last updated: December 30, 2025 at 11:02 AM Eastern Time
Review the recent VIRO stock performance trends:Past 1 Month: ViroGates (VIRO) shares have -21.57%.Past 3 Months: The stock has +33.17%.Past 6 Months: VIRO shares have +72.44%. Last updated: December 31, 2025 at 11:42 PM Eastern Time
Over the last year, ViroGates (VIRO) has established a 52-week price range between a high of DKK17.40 and a low of DKK5.98. This metric is essential for assessing the stock's annual volatility. Last updated: December 31, 2025 at 11:42 PM Eastern Time
ViroGates (VIRO) is considered a medium volatility stock. It has a beta of 0.90, which means it typically moves 0.90 times as much as the broader market. Over the past 52 weeks, VIRO has traded within a DKK5.98 – DKK17.40 range. Last updated: December 31, 2025 at 11:42 PM Eastern Time
A DKK1,000 investment in ViroGates 5 years ago, when the stock was trading around DKK81.53, would be worth approximately DKK164.97 today, based solely on share price performance (excluding dividends). This represents a total return of -83.50% over the period, equivalent to a compound annual growth rate (CAGR) of -30.26%. Past performance reflects historical price movements only and does not imply future results. Last updated: December 31, 2025 at 11:42 PM Eastern Time
The current ViroGates (VIRO) market capitalization is approximately DKK124.84M, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, ViroGates's market cap fluctuates with changes in its share price and share count. Last updated: December 31, 2025 at 11:42 PM Eastern Time
In the most recently reported quarter, ViroGates (VIRO) generated DKK1.67M in revenue, representing a -44.23% year over year change. Quarterly revenue results and expectations reflect underlying demand trends, pricing dynamics, product or service mix, seasonality, and broader macroeconomic conditions. Actual results may differ from consensus estimates as new information becomes available. Last updated: January 1, 2026 at 2:23 AM Eastern Time
In the most recently reported fiscal year, ViroGates (VIRO) generated net income of DKK-14.35M, compared with DKK-12.10M in the prior fiscal year, representing a -18.59% year over year change. Net income may be positive or negative and can fluctuate materially from year to year due to changes in operating performance, non-recurring or one-time items, accounting treatments, capital structure, and broader macroeconomic conditions. Last updated: January 1, 2026 at 2:23 AM Eastern Time
As of the most recent reporting period, the company's debt-to-equity ratio stands at 1.69x, calculated as total debt divided by total shareholders' equity. A lower debt-to-equity ratio generally indicates a more conservative capital structure with less reliance on external borrowing, while a higher ratio suggests greater financial leverage and potentially higher sensitivity to interest rates, refinancing conditions, and earnings volatility. The debt-to-equity ratio should be interpreted in the context of the company's industry, business model, cash flow stability, and balance sheet composition. Last updated: January 1, 2026 at 2:23 AM Eastern Time
Based on the latest available data, ViroGates (VIRO) is currently trading at a last twelve months (LTM) P/E ratio of -8.40x. The P/E ratio reflects how much investors are willing to pay today for a dollar of earnings and can vary meaningfully over time due to changes in profitability, growth expectations, margin outlook, and earnings volatility. Last updated: January 1, 2026 at 2:23 AM Eastern Time
In the most recently reported quarter, ViroGates (VIRO) revenue was DKK1.67M. Earnings per share (EPS) for the quarter were DKK-0.25. Revenue and EPS surprises may be positive or negative and can influence near-term stock performance depending on expectations, forward guidance, and broader market and sector conditions. For a detailed history of analyst expectations versus reported results, view the full estimates vs. actuals track record here: 👉 Estimates vs. Actuals Last updated: January 1, 2026 at 2:23 AM Eastern Time
ViroGates (VIRO) does not currently pay a dividend. Over the last twelve months (LTM), the company paid DKK0.00 per share in dividends, and no dividend payments are currently expected over the next twelve months (NTM). Companies that do not pay dividends typically prioritize reinvesting cash into growth initiatives, capital expenditures, debt reduction, or strategic investments, though dividend policy may change in the future. Last updated: January 1, 2026 at 2:23 AM Eastern Time
Based on the latest available analyst coverage, ViroGates (VIRO) currently carries a not available consensus rating. Analyst views are forward-looking estimates and should not be considered investment advice. Last updated: January 1, 2026 at 2:23 AM Eastern Time
Like other publicly traded stocks, ViroGates (VIRO) shares are bought and sold on stock exchanges such as CPSE and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for ViroGates (VIRO) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.
At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add VIRO to your watchlist.
ViroGates trades under the ticker symbol VIRO on the CPSE stock exchange. The ticker VIRO is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.
As of the most recently reported period, ViroGates (VIRO) employs approximately 7 people worldwide. Reported employee figures may fluctuate over time due to hiring activity, restructuring, automation initiatives, or changes in business strategy. Headcount data is typically disclosed in company filings and reflects full-time employees unless otherwise stated. Last updated: December 31, 2025 at 11:42 PM Eastern Time
ViroGates (VIRO) operates in a highly competitive market with companies that often have different business models, geographic exposure, and end markets. While no two companies are identical, the following firms are generally considered the closest ViroGates (VIRO) stock peers based on overlapping products, services, and competitive dynamics:Q-linea (QLINEA)Observe Medical (OBSRV)Neola Medical (NEOLA)Milton Essex Spólka Akcyjna (MTN)Acarix (ACARIX)Boule Diagnostics (BOUL)Medicon Hellas (MEDIC)CellaVision (CEVI) These peers may differ in size, business mix, financial profile, and strategic focus, but they are commonly referenced due to overlapping markets, customer segments, or competitive positioning relative to ViroGates.
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersNEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersGainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.